| James Baker, AA-C | |
|
11100 Euclid Ave, Cleveland, OH 44106-1716 | |
| (216) 844-3722 | |
| Not Available |
| Full Name | James Baker |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology Assistant |
| Experience | 9 Years |
| Location | 11100 Euclid Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710365143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367H00000X | Anesthesiologist Assistant | (* (Not Available)) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Hospitals Of Cleveland | Cleveland, OH | Hospital |
| University Hospitals Ahuja Medical Center | Beachwood, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Hospitals Medical Group Inc | 4789682493 | 1466 |
| University Primary Care Practices Inc | 3072417534 | 940 |
News Archive
President Obama's one-year plan to allow insurers to keep Americans on plans previously canceled under the health law's new standards faces several questions in implementation: Will insurers, customers and state regulators will go along? Also, The Wall Street Journal reports that the move could pave the way for the insurance plans to be extended beyond 2014.
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes: "On a cool weekday afternoon, a small group of young adults gathers outside Covenant House, a homeless shelter where some of them live or go to school.
› Verified 1 days ago
| Entity Name | University Primary Care Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003935339 PECOS PAC ID: 3072417534 Enrollment ID: O20031125000767 |
News Archive
President Obama's one-year plan to allow insurers to keep Americans on plans previously canceled under the health law's new standards faces several questions in implementation: Will insurers, customers and state regulators will go along? Also, The Wall Street Journal reports that the move could pave the way for the insurance plans to be extended beyond 2014.
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes: "On a cool weekday afternoon, a small group of young adults gathers outside Covenant House, a homeless shelter where some of them live or go to school.
› Verified 1 days ago
| Entity Name | University Hospitals Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669499414 PECOS PAC ID: 4789682493 Enrollment ID: O20061113000301 |
News Archive
President Obama's one-year plan to allow insurers to keep Americans on plans previously canceled under the health law's new standards faces several questions in implementation: Will insurers, customers and state regulators will go along? Also, The Wall Street Journal reports that the move could pave the way for the insurance plans to be extended beyond 2014.
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes: "On a cool weekday afternoon, a small group of young adults gathers outside Covenant House, a homeless shelter where some of them live or go to school.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James Baker, AA-C 11100 Euclid Ave, Cleveland, OH 44106-1716 Ph: (216) 844-3722 | James Baker, AA-C 11100 Euclid Ave, Cleveland, OH 44106-1716 Ph: (216) 844-3722 |
News Archive
President Obama's one-year plan to allow insurers to keep Americans on plans previously canceled under the health law's new standards faces several questions in implementation: Will insurers, customers and state regulators will go along? Also, The Wall Street Journal reports that the move could pave the way for the insurance plans to be extended beyond 2014.
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).
Researchers have investigated the effectiveness of a bioengineered miniprotein in protecting against SARS-CoV-2 infection in vivo. The researchers evaluated the miniprotein, LCB1, against SARS-CoV-2-mediated lung disease in human ACE2-expressing transgenic mice.
Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes: "On a cool weekday afternoon, a small group of young adults gathers outside Covenant House, a homeless shelter where some of them live or go to school.
› Verified 1 days ago
Shannon Kelly, AA-C Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Olivia Kehoe, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-1000 | |
Brian Michael Wheatley, Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Nicole M Moses, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Michael Marcotte, CAA Anesthesiologist Assistant Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Thomas Bruno, AA Anesthesiologist Assistant Medicare: Medicare Enrolled Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 | |
Gregory G Kychun, AA Anesthesiologist Assistant Medicare: Not Enrolled in Medicare Practice Location: 11100 Euclid Ave, Cleveland, OH 44106 Phone: 216-844-7330 |